Syra Health Posts Strong FY2025 Results with 157% Population Health Growth and 76% Net Loss Reduction: Targets Profitability by Year-End 2026

Rhea-AI Summary

Syra Health (SYRA) reported strong FY2025 results: population health revenue grew 157% to $5.3M and net loss narrowed 76% to ($896K) from ($3.8M). EPS improved to ($0.08) from ($0.50). Operating expenses declined 37% to $3.4M and gross margin rose to 34.4% from 20.7%.

The company ended 2025 with $1.6M cash, no long-term debt, launched new contracts and pilots, submitted Syrenity to FDA TEMPO, and expects profitability by year-end 2026.

Positive

• Population health revenue +157% to $5.3M in FY2025
• Net loss reduced 76% to ($896K) in FY2025
• Gross margin improved 14 percentage points to 34.4%
• Operating expenses down 37% to $3.4M in FY2025
• Adjusted EBITDA improved to ($863K) from ($3.7M)

Negative

• Weighted average shares outstanding rose 57% to 11.85M
• Total assets declined ~25% to $2.77M at year-end 2025
• Adjusted EBITDA remained a loss of ($863K) in 2025

News Market Reaction – SYRA

+5.00%

1 alert

+5.00% News Effect

On the day this news was published, SYRA gained 5.00%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

• FY2025 EPS improved to ($0.08) compared to ($0.50) in FY2024
• YoY net loss reduced 76% to ($896K) from ($3.8M) in FY2024
• Population health revenue grew 157% to $5.3 million versus $2.1 million in FY2024
• Operating expenses declined 37% to $3.4 million compared to $5.4 million in FY2024

CARMEL, Ind., March 12, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB: SYRA) ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today its financial results for the fourth quarter and full year ended December 31, 2025.

Q4 and Full Year 2025 Financial Highlights

• Population Health revenue grew 157% year-over-year to $5.3 million in FY2025 from $2.1 million in FY2024, driven by demand for the Company's higher margin yielding population health solutions, including data analytics, health education and training. Q4 2025 Population Health revenue grew 128% year-over-year to $1.3 million, compared to $550K in Q4 2024.
  
  
• Earnings per share improved by $0.42 in FY2025 to ($0.08) from ($0.50) in FY2024. Q4 2025 EPS improved to ($0.01) from ($0.08) in Q42024, representing meaningful progress as the Company moves closer to profitability.
  
  
• Total operating expenses declined 37% to $3.4 million in FY2025 when compared to $5.4 million in FY2024. Q4 2025 operating expenses decreased 13% to $727K from $836K in Q4 2024.
  
  
• Net loss improved 76% to ($896K) in FY2025 from ($3.8M) in FY2024. Q4 2025 net loss was reduced 73% to ($135K) versus ($504K) in Q4 2024, reflecting a significantly improved cost structure.
  
  
• Gross margin grew to 34.4% in FY2025 from 20.7% in FY2024, representing a 14 percentage point increase, attributed to improved operational efficiency and a higher-quality revenue mix.

2026 Financial Outlook

• The Company expects to achieve profitability by year-end 2026, driven by continued strong demand for its comprehensive population health solutions, disciplined cost management, and new contract wins.

Recent Operational Highlights

• Executed a strategic transformation from a healthcare technology provider to an integrated healthcare solutions company, delivering end-to-end capabilities for its government and commercial healthcare customers.
  
  
• Won a new training contract in Washington state to safeguard behavioral health workers from workplace violence, addressing a critical and growing need on the frontlines of care.
  
  
• Scaled our live-agent HEDIS call center operations and expanded utilization nursing staff to meet demand from insurance company customers.
  
  
• Launched a wellness pilot program in collaboration with a public health department in North Carolina to protect employees from secondary trauma.
  
  
• Submitted Syrenity for FDA approval under the FDA's TEMPO pilot program, positioning the Company to participate in CMS's ACCESS Model, a 10-year national initiative launching July 2026 that rewards improved patient outcomes in behavioral health.

Management Commentary

Greg Alexander, CEO of Syra Health, said, "2025 was a breakout year for Syra Health. Our team delivered on two fronts, driving 157% growth in Population Health revenue while aggressively restructuring our cost base, cutting our net loss by 76%, and improving gross margins by 14 percentage points. This combination of top-line momentum and bottom-line discipline is what gives us confidence in our path to profitability by year-end 2026. Our evolution into an integrated healthcare solutions company reflects the strength and breadth of our portfolio. We are proud of what our team has built, and we remain committed to delivering value for our shareholders and better health outcomes for the communities we serve across the U.S."

2025 Financial Results

For FY2025 ending December 31, revenue was $7.2 million, a 9% decrease compared to $8.0 million in FY2024, primarily due to the previously announced slowing or termination of federal government funding that supports many of the Company's customers at the state and county government level. 

Adjusted EBITDA for 2025 was ($863K) compared to ($3.7 million) in 2024, indicating significant year-over-year efficiency gains and improvement in the company's operational profitability.

Cash on hand was $1.6 million, and there was no long-term debt as of December 31, 2025.

 

Syra Health Corp
Balance Sheets
	December 31, 2025		December 31, 2024
ASSETS
Current assets:
Cash	$                   1,614,733		$              2,395,405
Accounts receivable, net	918,374		680,827
Other current assets	205,423		276,563
Total current assets	2,738,530		3,352,795
Property and equipment, net	6,986		27,347
Right of use asset	27,401		299,190
Total assets	$                   2,772,917		$              3,679,332
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$                      247,520		$                 101,690
Accounts payable, related parties	72,000		-
Accrued expenses	194,821		230,383
Deferred revenue	16,611		16,611
Current portion of operating lease liability, related party	27,401		111,978
Notes payable	116,386		152,887
Total current liabilities	674,739		613,549
Non-current portion of operating lease liability, related party	-		187,212
Total liabilities	674,739		800,761
Stockholders' equity:
Preferred stock, $0.001 per value, 10,000,000 shares authorized, none      issued	-		-
Class A Common stock, $0.001 par value, 100,000,000 shares authorized, 11,339,169 and 8,979,204 issued and outstanding at December 31, 2025 and 2024 respectively	11,339		8,979
Class B Common stock, $0.001 par value, 5,000,000 shares authorized, 600,000 and 833,334 issued and outstanding at December 31, 2025 and 2024 respectively	600		833
Additional paid in capital	11,806,765		11,692,952
Accumulated deficit	(9,720,526)		(8,824,193)
Total stockholders' equity	2,098,178		2,878,571
Total liabilities and stockholders' equity	2,772,917		$              3,679,332

 

Syra Health Corp
Statements of Operations
For the Years Ended December 31, 2025 and 2024
			December 31, 2025		December 31, 2024
Net revenues			$                 7,225,973		$               7,982,082
Cost of services			4,738,211		6,329,119
Gross profit			2,487,762		1,652,963
OPERATING EXPENSES:
Salaries and benefits			1,500,688		2,718,743
Professional services			737,714		606,051
Research and development expenses			67,840		585,146
Selling, general and administrative expenses			1,065,376		1,445,170
Depreciation			20,468		62,738
Total operating expenses			3,392,086		5,417,848
Net loss from operations			(904,324)		(3,764,885)
OTHER INCOME (EXPENSES):
Interest income			21,261		21,247
Interest expense			(13,270)		(15,600)
Total other income (expense)			7,991		5,647
NET INCOME (LOSS)			$                   (896,333)		$              (3,759,238)
Loss per common share, basic and diluted			$                         (0.08)		$                       (0.50)
Weighted average number of common shares      outstanding, basic and diluted			11,852,347		7,551,576

 

Syra Health Corp
Statements of Cash Flows
	For the Years Ended December 31, 2025 and 2024
		2025		2024
CASH FLOWS FROM OPERATING ACTIVITIES:
	Net Income (Loss)	$              (896,333)		$          (3,759,238)
	Adjustments to reconcile net loss to net cash used in operating activities:
	Depreciation Expense	20,468		62,738
	Common stock issued for services	2,586		71,378
	Stock-based compensation, stock options	98,554		59,803
	Non-cash lease expense	-		89,500
Changes in operating assets and liabilities:
	Accounts receivable	(237,547)		379,807
	Accounts receivable, related party	-		50,614
	Other current assets	382,258		491,883
	Right-of-use asset	105,670		-
	Accounts payable	145,830		(361,301)
	Accounts payable, related parties	72,000		-
	Deferred revenue	-		16,611
	Accrued expenses	(35,562)		55,672
	Operating lease liability	(105,670)		(89,500)
Net cash used in operating activities		(447,746)		(2,932,033)
CASH FLOWS FROM INVESTING ACTIVITIES:
	Purchases of property and equipment	(107)		(11,111)
Net cash provided by (used in) investing activities		(107)		(11,111)
CASH FLOWS FROM FINANCING ACTIVITIES:
	Proceeds received on exercise of Class A common stock warrants	14,800		2,469,150
	Repayment of notes payable	(347,619)		(410,676)
Net cash provided by financing activities		(332,819)		2,058,474
Net change in cash		(780,672)		(884,670)
Cash at beginning of period		2,395,405		3,280,075
Cash at end of period		$             1,614,733		$            2,395,405
Supplemental disclosure of cash flow information:
	Cash paid for interest	$                  13,270		$                 15,600
	Cash paid for taxes	-		-
Non-cash investing and financing activities:
	Conversion of Class B common stock to Class A common stock	$                    2,333		$                           -
	Initial recognition of right-of-use asset and lease liability	$                           -		$               325,491
	Amendment of right-of-use asset and lease liability	$                166,119		$                           -
	Options issued for director fees	$                           -		$                 24,267
	Prepaid asset financed with note payable	$                311,118		$               378,659

 

Non-GAAP Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ("GAAP"), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity, and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures. For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below.

Syra Health Corp EBITDA
	Year Ended
	December 31, 2025		December 31, 2024
Net Loss	$                (896,333)		$            (3,759,238)
Interest expense	13,270		15,600
Depreciation expense	20,468		62,738
Taxes	-		-
Earnings before Interest, Taxes Depreciation and Amortization	$                (862,595)		$            (3,680,900)
	Quarter ended
	December 31, 2025		December 31, 2024
Net Loss	$                (134,570)		$               (504,397)
Interest expense	5,369		5,528
Depreciation expense	2,297		7,278
Taxes	-		-
Earnings before Interest, Taxes Depreciation and Amortization	$                (126,904)		$               (491,591)

About Syra Health

Syra Health is an integrated healthcare solutions company serving government and commercial healthcare organizations with innovative solutions that improve health outcomes. We specialize in healthcare prevention, expanding access, and delivering affordable solutions. Our healthcare analytics capabilities provide proactive, actionable insights and data-driven intelligence, and our HIPAA-compliant and fully accessible digital health solutions enable measurable health outcomes in highly regulated healthcare environments. Through training and education, we help healthcare organizations reduce costs and deliver consistent, high-quality care.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact
Christine Drury
IR/PR
Syra Health
463-345-5180
christined@syrahealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-posts-strong-fy2025-results-with-157-population-health-growth-and-76-net-loss-reduction-targets-profitability-by-year-end-2026-302711575.html

SOURCE Syra Health

FAQ

What was Syra Health's FY2025 EPS and how did it change versus FY2024 (SYRA)?

FY2025 EPS improved to ($0.08), up from ($0.50) in FY2024, a $0.42 improvement. According to the company, this reflects improved margins, cost reductions and higher-margin population health revenue that materially narrowed the per-share loss for 2025.

How much did Syra Health's population health revenue grow in FY2025 (SYRA)?

Population health revenue increased 157% to $5.3 million in FY2025 versus FY2024. According to the company, this growth was driven by demand for data analytics, health education and training, and a higher-quality revenue mix improving margins.

When does Syra Health expect to reach profitability and what is the timeline (SYRA)?

Syra Health expects to achieve profitability by year-end 2026. According to the company, this target is based on continued population health demand, disciplined cost management, and anticipated new contract wins and operational efficiencies.

How strong is Syra Health's cash position at the end of 2025 (SYRA)?

Syra Health reported $1.6 million cash on hand as of December 31, 2025. According to the company, there was no long-term debt, but cash levels will influence near-term liquidity and execution of growth plans.

What is the significance of Syra Health's Syrenity FDA TEMPO submission for SYRA investors?

The Syrenity submission under FDA TEMPO positions Syra Health to participate in CMS's ACCESS Model launching July 2026. According to the company, FDA involvement could enable access to a 10-year CMS program that rewards improved behavioral health outcomes.